Abstract:Potential conflict of interest: Nothing to report. TO THE EDITOR: We read the article by Seo et al.,1 in which the investigators reported that exosomes secreted by hepatocytes increase Toll‐like receptor 3 (TLR3) expression in hepatic stellate cells (HSCs) and activate HSCs, with great interest. Interleukin (IL)‐17A released by the activated HSCs further promotes IL‐17A production by γδ T cells and exacerbates liver fibrosis. This study improved our understanding of the pathogenesis of liver fibrosis. Consistent with their findings, our center recently showed that IL‐17A increased liver injury in a different model of liver diseases.2 However, we have some questions about IL‐17A production by activated HSCs and the effects of TLR3 on liver fibrosis. The investigators noted that hepatocyte‐released exosomes activated HSCs and accelerated IL‐17A production by HSCs, which subsequently amplified IL‐17A production from γδ T cells.1 IL‐17 is primarily produced by CD4+IL‐17+ T (Th17) cells, as well as other immune cells, including γδ T cells, natural killer (NK) T cells, NK cells, receptor‐related orphan receptor gamma t (RORγt)+ neutrophils, and eosinophils.3 So far, there has been no evidence that quiescent or activated HSCs produce IL‐17A. Furthermore, our center previously reported that HSC activation may not up‐regulate IL‐17A expression in these cells.2 We believe that IL‐17A promotion may be derived from exosomes, rather than HSCs, as was described in Seo et al.'s study, during the CCl4‐induced liver fibrillation. Thus, the sources of IL‐17A promotion require further research. Moreover, data showed that TLR3 deficiency in HSCs markedly attenuates liver fibrosis. TLR3 is primarily expressed in macrophages and dendritic cells, rather than HSCs, in the liver.4 However, TLRs expressed on HSCs, including TLR4 and TLR9 among others, share similar downstream signaling pathways, such as myeloid differentiation primary response gene 88 and Toll/IL‐1 receptor‐domain‐containing adapter‐inducing interferon‐β.4 The function of TLR3 may be replaced by activation of the same downstream pathway by other TLRs, especially TLR4. Previous studies have even found that TLR3 can have a protective effect against liver fibrosis.5 Therefore, we question whether TLR3 expression by HSCs plays a strong promoting role in the development of liver fibrosis. We agree with the investigators' conclusion that exosomes and IL‐17 have substantial roles in development of liver fibrosis. However, further confirmation that IL‐17A production by activated HSCs subsequently amplifies IL‐17A production from γδ T cells, and that TLR3 expression by HSCs plays an independent promoting role in liver fibrosis, is needed.

Comment on “exosome‐mediated Activation of Toll‐like Receptor 3 in Stellate Cells Stimulates Interleukin‐17 Production by Γδ T Cells in Liver Fibrosis”

Exosome‐mediated activation of toll‐like receptor 3 in stellate cells stimulates interleukin‐17 production by γδ T cells in liver fibrosis

Regulatory Long Non-Coding RNAs of Hepatic Stellate Cells in Liver Fibrosis (Review)

The Etiology of Liver Damage Imparts Cytokines Transforming Growth Factor Beta 1 or Interleukin-13 As Driving Forces in Fibrogenesis

Interleukin-17 Signaling in Inflammatory, Kupffer Cells, and Hepatic Stellate Cells Exacerbates Liver Fibrosis in Mice

Interleukin-17 Promotes Activation of Human Hepatic Stellate Cells and Collagen Expression

Regulatory T cells (Tregs) in liver fibrosis

IL-17 and TNF-α co-operation contributes to the proinflammatory response of hepatic stellate cells

Il-17a Plays A Critical Role In The Pathogenesis Of Liver Fibrosis Through Hepatic Stellate Cell Activation

Extracellular Histones Stimulate Collagen Expression and Potentially Promote Liver Fibrogenesis Via TLR4-MyD88 Signalling Pathway

Hypoxia-inducible factor 1/IL-6 axis in activated hepatic stellate cells aggravates liver fibrosis

Interleukin-33 drives hepatic fibrosis through activation of hepatic stellate cells

Impaired Balance of T Helper 17/T Regulatory Cells in Carbon Tetrachloride-Induced Liver Fibrosis in Mice

HSC-derived exosomal miR-199a-5p promotes HSC activation and hepatocyte EMT via targeting SIRT1 in hepatic fibrosis

The HLF/IL-6/STAT3 Feedforward Circuit Drives Hepatic Stellate Cell Activation to Promote Liver Fibrosis

Γδt Cells Suppress Liver Fibrosis Via Strong Cytolysis and Enhanced NK Cell-Mediated Cytotoxicity Against Hepatic Stellate Cells

Expression of hepatic stellate cell activation-related genes in HBV-, HCV-, and nonalcoholic fatty liver disease-associated fibrosis

Single‐Cell Transcriptomic Analysis Reveals a Hepatic Stellate Cell–Activation Roadmap and Myofibroblast Origin During Liver Fibrosis in Mice

Cholangiocyte‐Derived Exosomal Long Noncoding RNA H19 Promotes Hepatic Stellate Cell Activation and Cholestatic Liver Fibrosis

Hepatocyte-derived exosomes deliver H2AFJ to hepatic stellate cells and promote liver fibrosis via the MAPK/STMN1 axis activation

Exosomes derived from natural killer cells inhibit hepatic stellate cell activation and liver fibrosis